RSPH: INVESCO S&P 500 EQUAL WEIGHT HEALTH CARE ETF
Share-split context: A forward split was recorded on Jul 17, 2023 with coefficient 10. A forward split turns each old share into multiple new shares and lowers the quoted price per share proportionally. Proportional ownership is unchanged at the split moment, so the split itself creates neither a gain nor a loss. The price-return figures in this report are already split-adjusted.
What this ETF is trying to do
The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) focuses on health care companies. Instead of giving more importance to the biggest companies, it uses an "equal weight" approach. This means it tries to give similar importance to the different health care companies in the S&P 500.
What the numbers show
When looking at this ETF, it is important to know the difference between price return and total return. Price return only shows how much the share price changed. Total return includes both the price change and any cash payments (distributions) you received.
The data shows that RSPH has grown in both areas:
• Year-to-Date (YTD): The price return is approximately 16.17%, while the total return is approximately 16.78%.
• One Year: The price return is approximately 22.64%, and the total return is approximately 23.49%.
• Three Years: The price return is approximately 35.28%, and the total return is approximately 38.19%.
This ETF has a history of share splits. In July 2023, there was a "forward split." This means each old share became 10 new shares. When this happens, the price per share drops proportionally, but your ownership in the fund stays exactly the same. The split itself does not create a gain or a loss for the investor.
Income and distribution explanation
Some investors look for cash payments from their investments. This ETF has a distribution yield of approximately 0.60%. These distributions are usually paid out quarterly (four times a year). While these payments provide cash, they are different from the total return of the fund.
NAV erosion explanation
"NAV erosion" is a term used to describe when the value of the actual assets held by the ETF goes down over time. For this ETF, the erosion-risk score is 100, and the label says "No price erosion detected." The severity is rated as "good," meaning there are no signs of significant price deterioration in the fund's value.
Pros
• The ETF has shown positive price returns and total returns over the last year and three years.
• There is no detected price erosion.
• Top Holdings include: Moderna Inc (5.37%), CRL (2.20%), Veeva Systems Inc Class A (2.17%), Regeneron Pharmaceuticals Inc (1.98%), Bio-Techne Corp (1.95%), IQVIA Holdings Inc (1.94%), Baxter International Inc (1.86%), Amgen Inc (1.85%), Abbott Laboratories (1.82%), and Merck & Co Inc (1.81%).
Cons
• The distribution yield is relatively low at approximately 0.60%.
• The list of holdings provided is only a partial list of the largest companies in the fund.
Beginner takeaway
RSPH is an ETF that tracks health care companies with equal weight. It has shown growth in both its share price and its total return over several years, and it currently shows no signs of NAV erosion.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | MODERNA INC | MRNA | 5.37% |
| 2 | n/a | CRL | 2.20% |
| 3 | VEEVA SYSTEMS INC CLASS A | VEEV | 2.17% |
| 4 | REGENERON PHARMACEUTICALS INC | REGN | 1.98% |
| 5 | BIO-TECHNE CORP | TECH | 1.95% |
| 6 | IQVIA HOLDINGS INC | IQV | 1.94% |
| 7 | BAXTER INTERNATIONAL INC | BAX | 1.86% |
| 8 | AMGEN INC | AMGN | 1.85% |
| 9 | ABBOTT LABORATORIES | ABT | 1.82% |
| 10 | MERCK & CO INC | MRK | 1.81% |